Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 12/20 | 0.37 |
| ▸ | CTSS | P25774 | 7/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31374987 | 1.00 | CA1 (0.39) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL583877 | 0.98 | CTSK (0.39) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL1492103 | 0.98 | CTSK (0.39) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL583878 | 0.98 | CTSK (0.39) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL15105800 | 0.97 | CA1 (0.39) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL28269476 | 0.97 | CA1 (0.39) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL15105955 | 0.95 | CA1 (0.40) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL2377942 | 0.95 | CA1 (0.40) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL2377936 | 0.95 | CA1 (0.40) | CA1CA2CA7KMT2AMEN1 | |
| SCHEMBL583993 | 0.88 | CTSK (0.36) | CA1CA2CA7KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| CN-119306790-A | Amide derivative, composition and use thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| US-9045492-B2 | Piperazine compounds | AMURA THERAPEUTICS LIMITED (GB) | 2015-06-02 | — | — | US | disclosed |
| EP-2719700-A1 | TETRAHYDROFURO(3,2-B)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | Amura Therapeutics Limited (GB) | 2014-04-16 | — | — | EP | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20130252969-A1 | Compounds | AMURA THERAPEUTICS LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8501744-B2 | Piperazine compounds | AMURA THERAPEUTICS, LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
| US-20110077254-A1 | COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2011-03-31 | — | — | US | disclosed |
| EP-2240491-A2 | COMPOUNDS | Amura Therapeutics Limited (GB) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009144450-A1 | TETRAHYDROFURO [3, 2-B] PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-12-03 | — | — | WO | disclosed |
| WO-2009087379-A2 | TETRAHYDROFURO (3, 2 -B) PYRROL- 3 -ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009087379-A2 | TETRAHYDROFURO (3, 2 -B) PYRROL- 3 -ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LIMITED (GB) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | CA1 3326/4885CA2 1783/4885CA7 2417/4885 |
| US-20110077254-A1 | COMPOUNDS | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | CA1 2522/4885CA2 1786/4885CA7 1798/4885 |
| US-20130252969-A1 | Compounds | CHRM1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PRMT9 | CA1 2483/4885CA2 1751/4885CA7 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.